Compare Danaos Corporation (DAC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Danaos Corporation (DAC) trades at $137.35, down 0.7% on the day, but maintains strong technical and fundamental momentum. The stock shows a bullish technical signal with key support at $133 and resistance at $138. Fundamentally, DAC demonstrates exceptional profitability with a 51.26% net income margin and attractive valuation metrics including a P/E of 4.57 and P/B of 0.61. Recent Q2 2026 earnings beat expectations with EPS of $7.29 versus $6.80 expected, continuing a pattern of strong quarterly performance.

DAC presents a compelling value opportunity with deep discount to book value and consistent earnings outperformance. The company's record $4.6 billion contracted revenue backlog provides visibility, while quarterly dividends of $0.90 per share enhance shareholder returns. Primary risks include shipping industry cyclicality and capital expenditure requirements for fleet expansion. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's value proposition balanced against sector dynamics.

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.